NIR‐Light‐Triggered Mild‐Temperature Hyperthermia to Overcome the Cascade Cisplatin Resistance for Improved Resistant Tumor Therapy

Author:

Chen Mingmao1ORCID,Fu Yulei1,Liu Yan2ORCID,Zhang Baihe1,Song Xiaorong3,Chen Xinchun1,Zhu Zhengjia1,Gao Hang2,Yang Jianmin14,Shi Xianai14

Affiliation:

1. College of Biological Science and Engineering Fuzhou University Fuzhou 350108 China

2. CAS Key Laboratory of Design and Assembly of Functional Nanostructures Fujian Key Laboratory of Nanomaterials and State Key Laboratory of Structural Chemistry Fujian Institute of Research on the Structure of Matter Chinese Academy of Sciences Fuzhou 350002 China

3. MOE Key Laboratory for Analytical Science of Food Safety and Biology State Key Laboratory of Photocatalysis on Energy and Environment College of Chemistry Fuzhou University Fuzhou 350108 China

4. Fujian Key Laboratory of Medical Instrument and Pharmaceutical Technology Fuzhou University Fuzhou 350108 China

Abstract

AbstractCurrently, cisplatin resistance has been recognized as a multistep cascade process for its clinical chemotherapy failure. Hitherto, it remains challenging to develop a feasible and promising strategy to overcome the cascade drug resistance (CDR) issue for achieving fundamentally improved chemotherapeutic efficacy. Herein, a novel self‐assembled nanoagent is proposed, which is constructed by Pt(IV) prodrug, cyanine dye (cypate), and gadolinium ion (Gd3+), for systematically conquering the cisplatin resistance by employing near‐infrared (NIR) light activated mild‐temperature hyperthermia in tumor targets. The proposed nanoagents exhibit high photostability, GSH/H+‐responsive dissociation, preferable photothermal conversion, and enhanced cellular uptake performance. In particular, upon 785‐nm NIR light irradiation, the generated mild temperature of ≈ 43 °C overtly improves the cell membrane permeability and drug uptake, accelerates the disruption of intracellular redox balance, and apparently enhances the formation of Pt‐DNA adducts, thereby effectively overcoming the CDR issue and achieves highly improved therapeutic efficacy for cisplatin‐resistant tumor ablation.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Fujian Province

Publisher

Wiley

Subject

Pharmaceutical Science,Biomedical Engineering,Biomaterials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3